Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib with 7+3 Induction for AML
NCT02905994Phase 1Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volasertib in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose at 2 years. Planned start Sep 2016; status: withdrawn.
02
Drugs
volasertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02905994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905994.